BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $2 | $2 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 36% | 22.4% | 72.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 97.2% | 98.6% | 97.6% | 95.4% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 2.8% | -35.1% | -53.1% | -77.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -19.7% | -68.4% | -91.2% | -117.1% |
| EPS Diluted | -0.43 | -1.18 | -1.33 | -1.03 |
| % Growth | 63.6% | 11.3% | -29.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |